Posts

Posted on

Denison University Expands Partnership with Kaplan to Offer All of its Students and Alumni Free Comprehensive Prep for Graduate-Level Admissions Exams

Denison University Expands Partnership with Kaplan to Offer All of its Students and Alumni Free Comprehensive Prep for Graduate-Level Admissions Exams

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
Denison University, a private liberal arts college in Granville, Ohio, has expanded its partnership with global educational services provider Kaplan. Denison students and recent graduates now have free access to Kaplan’s best-in-class preparation for professional licensing exams, graduate-level admissions exams, and credential exams, including comprehensive prep for the GRE®, GMAT®, LSAT®, MCAT®, securities exam, and more. They also have access to a suite of professional and academic skills development courses from Kaplan.

Kim Canning, vice president of university partnerships, Kaplan, said:

“Denison University is making a powerful investment in its students and alumni by expanding access to free test prep and skills development courses, which can be truly transformative in their educational and career paths. We’re proud to support Denison in their efforts to open more doors, and look forward to welcoming their students and alumni into our classrooms.”

By investing in Kaplan’s All Access License™, colleges and universities can help their students prepare for a variety of high-stakes admissions and licensing exams that they need to score well on to reach their ultimate professional goals — with zero out-of-pocket costs for students. Kaplan has prepared students for standardized tests for more than 85 years, and Denison is its latest All Access License™ partner, joining Cleveland State University, Xavier University of Louisiana, Howard University, and Spelman College, among many others. In February, the Illinois Student Assistance Commission (ISAC), the state’s college access and financial aid agency, contracted Kaplan to provide free test preparation courses to all students enrolled in Illinois’ 12 public universities; five Illinois community colleges are also included as part of a pilot program. And most recently, the State University of New York began collaborating with Kaplan to provide 1,500 students in its SUNY Arthur O. Eve Educational Opportunity Program (EOP) with free test prep. The Higher Education Opportunity Program Professional Organization also rolled out their investment for many of its students too.

For college and university leaders who want to explore partnering with Kaplan, learn more about the company’s exam prep programs.

Test names and other trademarks are the property of the respective trademark holders.

About Kaplan

Kaplan, Inc. is a global educational services company that helps individuals and institutions advance their goals in an ever-changing world. Our broad portfolio of solutions help students and professionals further their education and careers, universities and educational institutions attract and support students, and businesses maximize employee recruitment, retainment, and development. Stanley Kaplan founded our company in 1938 with a mission to expand educational opportunities for students of all backgrounds. Today, our thousands of employees working in 27 countries/regions continue Stanley’s mission as they serve about 1.3 million students and professionals, 16,000 corporate clients, and 2,700 schools, school districts, colleges, and universities worldwide. Kaplan is a subsidiary of the Graham Holdings Company (NYSE: GHC). Learn more at kaplan.com.

Note to editors: Kaplan is a subsidiary of Graham Holdings Company (NYSE: GHC)

Press Contact: Russell Schaffer, [email protected]

Twitter: @KaplanEdNews

KEYWORDS: United States North America Florida Ohio

INDUSTRY KEYWORDS: Education Other Education Continuing University

MEDIA:

Logo
Logo
Posted on

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

  • 90-day trial measuring change in general fatigue in chronic babesiosis patients
  • Enrollment expected to commence Q4 2025 and to be completed by Q2 2026
  • Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosis
  • No FDA-approved treatment exists for chronic babesiosis, a debilitating illness

WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today it has signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York City as the central site for a Phase II clinical study of tafenoquine in treating chronic babesiosis.

For the purposes of the study, chronic babesiosis is defined as a patient with disabling fatigue of at least six months duration, with other symptoms, and laboratory confirmation of, babesiosis.

The open-label study (NCT06656351) will evaluate the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days, treating patients with a presumptive diagnosis of chronic babesiosis. The primary endpoint will be resolution of fatigue assessed using a patient reported outcome measure (the multi-dimensional fatigue inventory general fatigue subscale) at Day 90 compared with baseline. Participants will have experienced significant functional impairment for at least six months. Tafenoquine (2 x 100 mg tablets) will be self-administered orally with food on Days 1, 2, 3, 4, then weekly thereafter for a total 12-week treatment period. Weekly treatment will start on Day 11 and end on Day 89.

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the United States Food and Drug Administration for such an indication.

“We are pleased to welcome the Icahn School of Medicine at Mount Sinai research team into the 60 Degrees Pharma tafenoquine for babesiosis clinical trial program,” said 60 Degrees Pharmaceuticals, Inc. Chief Executive Officer, Geoff Dow, PhD. “They bring deep expertise and skill in researching tick-borne illnesses, along with a focus on supporting the development of novel therapies to meet the critical unmet needs of patients with chronic disease.”

Clinical Babesiosis Studies Sponsored by 60 Degrees Pharmaceuticals

Three 60 Degrees Pharmaceuticals-sponsored clinical trials (NCT06478641, NCT06207370, NCT06656351) are underway or planned to evaluate tafenoquine’s safety and efficacy in treating humans diagnosed with babesiosis. Data are expected from one or more of these studies in the first half of 2026 and will be used as part of a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration for babesiosis, anticipated in 2026.

About Babesiosis

Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening threatening in elderly and immunosuppressed patients. Incidence of the disease is rapidly rising, particularly in the Northeast. Transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease, babesiosis is an orphan disease. Babesia infection may persist for at least a year; fatigue is usually the symptom of infection that takes longest to resolve and may be debilitating over the long term in some patients.

About ARAKODA® (tafenoquine)

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months.

Tafenoquine was discovered by Walter Reed Army Institute of Research and the current study was funded by the United States Army Medical & Materiel Development Activity. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug.

According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.

ARAKODA® (tafenoquine) Important Safety Information

ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

Contraindications

ARAKODA® should not be administered to:

  • Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;
  • Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if
  • G6PD status is unknown;
  • Patients with a history of psychotic disorders or current psychotic symptoms; or
  • Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®.

Warnings and Precautions

Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.

G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.

Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.

Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible.

Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.

Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.

Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety.

Drug Interactions

Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters.

Use in Specific Populations

Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA® is located here.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of Its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:
Sheila A. Burke
[email protected]
(484) 667-6330

Investor Contact:
Patrick Gaynes
[email protected]
(310) 989-5666



Posted on

Pearl Diver Credit Company Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call

PR Newswire


– Conference Call Scheduled for Tuesday, August 26, 2025 at 11:00 am Eastern Time / 4:00 pm UK Time –


NEW YORK and LONDON, Aug. 19, 2025 /PRNewswire/ — Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA) (the “Company”) today announced that its second quarter 2025 financial results will be released prior to market open on Tuesday, August 26, 2025. The Company will also host a conference call and webcast at 11:00am Eastern Time / 4:00pm UK time on the same day to discuss its financial results.

PDCC to announce Q2 2025 financial results on Tuesday, August 26, 2025.

Investors and analysts interested in participating in the call are invited to dial 1-877-407-9208 (US callers) or 1-201-493-6784 (international callers) and ask for the Pearl Diver Credit Company Inc. Second Quarter 2025 Earnings Call. All participants should dial-in approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will also be available on the Company’s website at https://pearldivercreditcompany.com/.

An archived replay of the conference call will be available within two hours of the conclusion of the call and can be accessed online on the Company’s website.

About Pearl Diver Credit Company Inc.
Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA) is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to maximize its portfolio’s total return, with a secondary objective of generating high current income. The Company seeks to achieve these objectives by investing primarily in equity and junior debt tranches of CLOs collateralized by portfolios of sub-investment grade, senior secured floating-rate debt issued by a large number of distinct US companies across several industry sectors. The Company is externally managed by Pearl Diver Capital LLP. For more information, visit www.pearldivercreditcompany.com.

About Pearl Diver Capital LLP
Founded in 2008, Pearl Diver Capital specializes in collateralized loan obligation (CLO) investing. Its data scientists and credit analysts use proprietary technology and advanced analytics to identify attractive opportunities in the CLO market. Pearl Diver’s highly experienced team includes individuals from a wide range of scientific and mathematical backgrounds.

As of June 30, 2025, Pearl Diver Capital has approximately $3.0 billion in assets under management across multiple private funds backed by institutional investors ranging from public pension plans, university endowments, foundations, large family offices, corporate/ERISA pension plans and asset managers across the US, Europe and Latin America.  Because it is strictly an investor in the CLO space, not an issuer, it has developed close relationships with over 80 CLO managers – and their analysts – across the CLO spectrum, enabling the firm to have rare access to critical credit information on underlying companies in CLO portfolios while avoiding conflicts of interest that might arise in performing roles that span both CLO investing and CLO management. For more information, visit www.pearldivercapital.com.

Investor Contact:
[email protected]
UK: +44 (0)20 3967 8032
US: +1 617 872 0945

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pearl-diver-credit-company-inc-schedules-second-quarter-2025-earnings-release-and-conference-call-302533455.html

SOURCE Pearl Diver Credit Company Inc.

Posted on

Billion Dollar Autonomous Technology Sector Poised for Significant Revenue and Growth Opportunities

PR Newswire


MarketNewsUpdates


News Commentary


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — In the rapidly growing Artificial Intelligence market, the adoption of Autonomous & Sensor Technology is driving considerable growth. Factors such as increasing awareness of the benefits of AI and the convenience of online services are contributing to this growth rate. Understanding what impact this technology will have on a growing number of industries at present, enterprises in sectors such as government operations, security and threat detection industry, automotive, manufacturing, mining and utilities, have been especially effective at using autonomous technologies to achieve greater efficiency, safety and to achieve sustainability. According to Verified Market Reports, Trends such as the revolution in autonomous vehicles, expansion of drones and UAVs, adoption of autonomous robots in manufacturing, development of autonomous ships, integration in agriculture, AI-powered autonomous systems, and the establishment of regulatory frameworks are shaping this dynamic landscape. A report from Statista.com projected that the market size in the Autonomous & Sensor Technology market is projected to reach US$32.85 billion in 2025 and the market size is expected to show an annual growth rate (CAGR 2025-2031) of 13.10%, resulting in a market volume of US$68.75 billion by 2031. In global comparison, the largest market size will be United States (US$9.67 billion in 2025). The report said: “As the adoption of autonomous and sensor technology increases, there is a growing trend towards personalized and intuitive user experiences. Consumers are seeking AI-powered solutions that can automate tasks and enhance overall efficiency, particularly in areas such as transportation and logistics.In addition, there is a growing demand for AI-driven safety and security systems, driven by concerns over data privacy and the need for more reliable and accurate monitoring and surveillance. This shift towards AI-driven solutions is also fueled by the increasing integration of smart devices and connected technologies in daily life.”  Active Companies leading the way with innovation in autonomous and artificial intelligence operations include VisionWave Holdings Inc. (NASDAQ: VWAV), Mobileye Global Inc. (NASDAQ: MBLY), AEye, Inc. (NASDAQ: LIDR), NVIDIA Corporation (NASDAQ: NVDA), Palantir Technologies Inc. (NASDAQ: PLTR).

Statista.com continued: “In the Autonomous & Sensor Technology Market within the Artificial Intelligence Market, there is a growing trend towards the integration of AI with various sensor technologies, such as LiDAR and radar, to enhance autonomous capabilities in industries like transportation and manufacturing. Additionally, there is a significant focus on developing AI-powered sensors that can collect and analyze large amounts of data in real-time, enabling faster decision-making and improved efficiency. These trends are expected to have a significant impact on industry stakeholders, including increased deployment of autonomous systems and improved safety and productivity in various sectors. Local special circumstances: In Japan, the Autonomous & Sensor Technology Market within the Artificial Intelligence Market is seeing rapid growth due to the country’s aging population and strict regulatory framework. The demand for AI-powered healthcare solutions is high as Japan faces a shortage of healthcare professionals. Additionally, the country’s culture of efficiency and automation has led to the adoption of AI in various industries, including healthcare.”

VisionWave (NASDAQ: VWAV) – Leading Live-Fire Radar Showcasing Defense Capabilities – VisionWave Holdings Inc. ($VWAV), (“VisionWave” or the “Company”), a defense technology company specializing in AI-powered sensing and autonomous threat-response systems, today announced two intellectual property updates that seek to strengthen its technology and intellectual property strategy. VisionWave has accelerated prosecution of a continuation patent related to its Radio Wave Finder technology. Further, VisionWave is introducing Evolved Intelligence™ (EI), VisionWave’s real-time, embedded AI engine designed for defense-grade autonomy at the edge.

USPTO update – Radio Wave Finder continuation – On August 12, 2025, the U.S. Patent and Trademark Office (“USPTO”) issued a first Office Action on the Company’s continuation application. The Office Action raised a procedural double-patenting matter that can be addressed via a Terminal Disclaimer; no other substantive issues were identified. VisionWave filed its formal response – including a Terminal Disclaimer – on August 18, 2025, to help expedite examination. The Company filed its response six days after the Office Action, demonstrating timely attention to IP matters. Patent issuance is not guaranteed until granted by the USPTO. The continuation describes a multi-planar radio-wave detection and imaging system with an AI analysis component for use across air, water, ground, and space domains.

Technology Momentum – Evolved Intelligence™ (EI) – EI is VisionWave’s real-time, embedded AI engine engineered for split-second, on-device decision-making in contested or bandwidth-limited environments. Its modular architecture combines multi-modal sensor fusion with a deterministic, edge-optimized runtime to deliver low-latency perception, prediction, and control across drones, unmanned ground vehicles, guided munitions, sensors and humanoid robotics. EI is intended to serve as a common autonomy layer across sensors and platforms. Separately, VisionWave has filed a U.S. trademark application for EVOLVED INTELLIGENCE™ (Serial No. 99317884); registration is not guaranteed and remains subject to standard USPTO examination.

Management commentary – Noam Kenig, Chief Executive Officer, VisionWave said “EI is designed to combine logic- and data-driven models with an added reasoning layer, with the goal of enabling more context-aware decision support in real time.” Mr. Kenig continued “our RF-to-image sensing approach is being developed to improve range and reduce clutter in contested environments.”

“EI is built for deterministic, low-latency decisions at the edge. Our patent-pending multi-planar RF-to-image sensing architecture synchronizes phased arrays with on-device inference to reconstruct high-fidelity target signatures from sparse emissions – cutting clutter and boosting range and precision. Coupled with EI’s fusion layer, it is being developed with the goal of improving range and precision in contested EW environments” added, Dr. Danny Rittman, Chief Technology Officer, VisionWave

Recent U.S. government initiatives and semiconductor programs underscore broader demand trends for edge-based autonomy. While VisionWave’s technologies may be applicable in these areas, the Company has not entered into agreements under such programs. VisionWave’s recent IP filings reflect an ongoing strategy to strengthen protection of its inventions and related brand assets.

Below is a summary of VisionWave EI offering:

  • Deterministic edge autonomy: bounded-latency inference and control for mission-critical timing.
  • Multi-modal fusion: radar/RF/EO/IR/system-health unified into a coherent operating picture.
  • Patent-pending RF-to-image sensing: multi-planar architecture designed to reduce clutter and enhance range/precision.
  • Scalable runtime: modular, hardware-agnostic deployment across air, land, sea, and stationary sensors.
  • IP + TM protection: expanding patent estate plus the EVOLVED INTELLIGENCE™ trademark to protect the technology and brand assets.
  • Program-ready posture: designed for comms-denied/GPS-denied operations and export-control-aware integrations. Continued…Read this full release and additional news for VWAV by visiting: https://finance.yahoo.com/quote/VWAV/news/

Other recent developments in the Autonomous/A.I.  industries include:

AIR, a pioneering startup offering eVTOL aircraft for uncrewed commercial and contested logistics, piloted personal flight, and defense use, recently announced that it has raised $23 million in Series A funding. The round was led by Entrée Capital, with participation from Dr. Shmuel Harlap, renowned businessman and an initial backer of Mobileye Global Inc. (NASDAQ: MBLY), who has also been an investor in AIR since its inception. The funding will enable AIR to further scale its eVTOL (electric vertical takeoff and landing) aircraft production in support of a growing number of purchase orders and accelerate its U.S. expansion efforts.

This momentum reflects a growing global demand for next-generation air mobility, further underscored by the U.S. government’s recent Executive Order promoting eVTOL production and integration and the recent FAA MOSAIC ruling updating the light sport aircraft (LSA) certification qualifications to include eVTOL type aircraft such as the AIR ONE. AIR is uniquely positioned to meet these rigorous standards, making it one of the first eVTOL aircraft expected to receive LSA certification.

AEye, Inc. (NASDAQ: LIDR), a pioneer in high-performance lidar technology and creator of both the Apollo lidar sensor and the OPTIS full-stack lidar solution, recently announced that its flagship Apollo lidar has been fully integrated by NVIDIA Corporation (NASDAQ: NVDA) into their DRIVE AGX platform, a critical part of NVIDIA’s highly touted autonomous vehicle ecosystem.

NVIDIA’s designation gives AEye direct access to a global network of top-tier automakers who are currently working with NVIDIA to implement self-driving and next-generation driver assistance technologies. It’s a major step toward getting AEye’s technology into millions of passenger vehicles in the coming years.

AEye CEO Matt Fisch commented, “We are thrilled to now be officially certified as a part of NVIDIA’s DRIVE AGX platform, a strong validation of Apollo’s best-in-class capabilities. Apollo’s industry-leading 1-kilometer range and compact form factor make it a standout solution across every market we serve. Now that Apollo is a part of the NVIDIA DRIVE ecosystem, we have a powerful channel to scale commercially across the automotive industry.”

Unstructured, a leader in enabling scalable, mission-ready Generative AI (GenAI) applications through advanced data transformation and orchestration solutions, announced that it has joined Palantir Technologies Inc. (NASDAQ: PLTR) FedStart program. The FedStart program aims to accelerate Unstructured’s journey toward FedRAMP High and IL-5 compliance, allowing government agencies to rapidly adopt secure, AI-ready data solutions.

FedStart is Palantir’s strategic initiative to assist innovative companies in navigating the complex process of achieving FedRAMP authorization and Department of Defense (DoD) Impact Level (IL) accreditation. Through this program, Unstructured will leverage Palantir’s established security and compliance expertise, significantly reducing the time required to achieve FedRAMP High authorization, IL-5 compliance, and Authority to Operate (ATO) for federal deployments.

DISCLAIMER:  MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  MNU is NOT affiliated in any manner with any company mentioned herein.  MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  MNU’S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  MNU is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed MNU has been compensated forty nine hundred dollars for news coverage of the current press releases issued by VisionWave Holdings, Inc. by the Company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [email protected] – +1(561)486-1799

Logo – https://mma.prnewswire.com/media/2737336/5465834/MarketNewsUpdates.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/billion-dollar-autonomous-technology-sector-poised-for-significant-revenue-and-growth-opportunities-302532756.html

SOURCE MarketNewsUpdates

Posted on

Class Action Filed Against CTO Realty Growth, Inc. (CTO) – October 7, 2025 Deadline to Join – Contact Levi & Korsinsky

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in CTO Realty Growth, Inc. (“CTO Realty Growth, Inc.” or the “Company”) (NYSE: CTO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CTO Realty Growth, Inc. investors who were adversely affected by alleged securities fraud between February 18, 2021 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/cto-realty-growth-inc-lawsuit-submission-form?prid=162050&wire=4 

CTO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) CTO’s dividends were less sustainable than defendants had led investors to believe; (ii) the Company used deceptive and unsustainable practices to artificially inflate its adjusted funds from operations and overstate the true profitability of its Ashford Lane property; (iii) accordingly, CTO’s business and/or financial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in CTO Realty Growth, Inc. during the relevant time frame, you have until October 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-cto-realty-growth-inc-cto—october-7-2025-deadline-to-join–contact-levi–korsinsky-302532963.html

SOURCE Levi & Korsinsky, LLP

Posted on

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=162049&wire=4

ALT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial.  Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Altimmune during the relevant time frame, you have until October 6, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-altimmune-incalt-urged-to-join-class-action–contact-levi–korsinsky-to-learn-more-302532961.html

SOURCE Levi & Korsinsky, LLP

Posted on

Investors in Lineage, Inc. Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights – LINE

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Lineage, Inc. (“Lineage, Inc.” or the “Company”) (NASDAQ: LINE) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lineage, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all purchasers of Lineage common stock in or traceable to the registration statement used in connection with the Company’s July 26, 2024 initial public offering.  Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/lineage-inc-lawsuit-submission-form?prid=162047&wire=4

LINE investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (b) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (c) Lineage was unable to effectively counteract the adverse trends listed in (a)-(b) above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (d) that, as a result of (a)-(c) above, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (e) that, as a result of (a)-(d) above, Lineage’s financial results, business operations, and prospects were materially impaired.

WHAT’S NEXT? If you suffered a loss in Lineage, Inc. during the relevant time frame, you have until September 30, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-in-lineage-inc-should-contact-levi–korsinsky-before-september-30-2025-to-discuss-your-rights–line-302532950.html

SOURCE Levi & Korsinsky, LLP

Posted on

KinderCare Learning Companies, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – KLC

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in KinderCare Learning Companies, Inc. (“KinderCare Learning Companies, Inc.” or the “Company”) (NYSE: KLC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of KinderCare Learning Companies, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s October 2024 initial public offering Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/kindercare-learning-companies-inc-lawsuit-submission-form?prid=162051&wire=4

KLC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (b) KinderCare did not provide the “highest quality care possible” at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (c) as a result of (a)-(b) above, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss.

WHAT’S NEXT? If you suffered a loss in KinderCare Learning Companies, Inc. during the relevant time frame, you have until October 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kindercare-learning-companies-inc-sued-for-securities-law-violations–investors-should-contact-levi–korsinsky-for-more-information–klc-302532958.html

SOURCE Levi & Korsinsky, LLP

Posted on

Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S(NVO)

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=162046&wire=4 

NVO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth.   On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on “lowered growth expectations for the second half of 2025” for both Wegovy and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.”  Following this news, the price of Novo’s common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo’s stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Novo during the relevant time frame, you have until September 30, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-levi–korsinsky-by-september-30-2025-deadline-to-join-class-action-against-novo-nordisk-asnvo-302532962.html

SOURCE Levi & Korsinsky, LLP

Posted on

Investors in Tesla, Inc. Should Contact Levi & Korsinsky Before October 3, 2025 to Discuss Your Rights – TSLA

PR Newswire


NEW YORK
, Aug. 19, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Tesla, Inc. (“Tesla, Inc.” or the “Company”) (NASDAQ: TSLA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Tesla, Inc. investors who were adversely affected by alleged securities fraud between April 19, 2023 and June 22, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/tesla-inc-lawsuit-submission-form-2?prid=162048&wire=4

TSLA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Tesla overstated the effectiveness of its autonomous driving technology; (ii) there was thus a significant risk that the Company’s autonomous driving vehicles, including the Robotaxi, would operate dangerously and/or in violation of traffic laws; (iii) the foregoing increased the likelihood that Tesla would become subject to heightened regulatory scrutiny; (iv) accordingly, Tesla’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times

WHAT’S NEXT? If you suffered a loss in Tesla, Inc. during the relevant time frame, you have until October 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-in-tesla-inc-should-contact-levi–korsinsky-before-october-3-2025-to-discuss-your-rights–tsla-302532965.html

SOURCE Levi & Korsinsky, LLP